Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.02 USD | -3.93% |
|
+7.74% | +210.22% |
Jul. 09 | Arcutis Biotherapeutics Gets FDA Approval for Atopic Dermatitis Supplemental NDA | DJ |
Jul. 09 | Arcutis Biotherapeutics' Zoryve Gets US FDA Approval for Atopic Dermatitis | MT |
Evolution of the average Target Price on Arcutis Biotherapeutics, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
![Consensus](/images/consensus_flch.gif)
Consensus detail
Consensus revision (last 18 months)
Analysts covering Arcutis Biotherapeutics, Inc.
Needham & Co. | |
Mizuho Securities | |
Morgan Stanley | |
JonesTrading Institutional Services | |
Goldman Sachs | |
Truist Securities | |
Guggenheim |
EPS Revisions
- Stock Market
- Equities
- ARQT Stock
- Consensus Arcutis Biotherapeutics, Inc.